Biotech Values

[mcbio]

As noted in my reply to Peter, I think the main advantage relative to the existing TNF-a biologics may be in lower COGS.

Yeah price is the biggie I left out, although I assume there won't be much, if any, advantage on this front for Ablynx's drug compared to the oral offerings to come, let alone the generic biologics on down the road.